SCHEMBL19637232

SCHEMBL19637232

CCc1c(C)nc(Cl)nc1N1CCNC(CC#N)C1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 1/20 0.33
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25021052 0.76 KRAS (0.39) —
SCHEMBL25021516 0.76 KRAS (0.39) —
SCHEMBL23841610 0.75 — —
SCHEMBL22725410 0.75 — —
SCHEMBL28501696 0.73 — —
SCHEMBL26528036 0.73 HTR6 (0.31) —
SCHEMBL28501694 0.73 — —
SCHEMBL28487072 0.73 — —
SCHEMBL22709886 0.72 HTR2C (0.30) —
SCHEMBL22709284 0.72 HTR2C (0.30) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
Send feedback